Physician

Mark A Gonce, M.D.

According to 2025 Medicare claims, Mark Gonce, M.D. (NPI: 1295732840) practices ophthalmology in the Charlottesville, VA market, with the plurality of this provider's patient population coming from Charlottesville City, VA. This provider's primary affiliated billing organization is CHARLOTTESVILLE EYE ASSOCIATES LTD (NPI: 1548200280; TIN: 54-1056576) and primary practice location at 22911-8672.

Gonce's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,870 traditional Medicare patients, billed 2,971 HCPCS/CPT codes, and received $337,891 in Medicare payments. The top billing code was 66984 (Removal of cataract with insertion of prosthetic lens). Part D data shows 1,161 prescription claims across 387 beneficiaries totaling $80,951 in drug costs, led by Lumigan (Bimatoprost). DME data shows 85 claims. Open Payments data shows 10 records totaling $232. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have declined steadily, from $158,496 to $80,951. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,110	3,754	$351,946
2016	2,205	3,918	$393,283
2017	2,057	3,507	$387,340
2018	1,970	3,352	$401,842
2019	1,980	3,427	$451,296
2020	1,828	3,071	$373,214
2021	2,048	3,409	$392,626
2022	2,109	3,477	$398,418
2023	1,943	3,205	$356,001
2024	1,870	2,971	$337,891

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	461	1,738	$158,496
2016	518	1,793	$179,046
2017	473	1,585	$145,261
2018	441	1,430	$137,474
2019	458	1,814	$132,535
2020	389	1,373	$98,570
2021	365	1,141	$103,707
2022	425	1,258	$111,496
2023	383	1,147	$91,889
2024	387	1,161	$80,951

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	154	154	$10,076
2016	193	195	$12,902
2017	171	171	$11,541
2018	123	124	$7,175
2019	169	169	$11,032
2020	168	168	$10,321
2021	136	138	$9,282
2022	145	145	$9,421
2023	61	61	$4,525
2024	83	85	$6,070

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
66984	Removal of cataract with insertion of prosthetic lens	238	337	$428
92014	Established patient complete exam of visual system	1,431	1,458	$81
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	132	139	$80
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	114	131	$38
92136	Measurement of corneal curvature and depth of eye	255	362	$28

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lumigan	Bimatoprost	29	1,803	$18,943
Restasis	Cyclosporine	12	840	$17,604
Prednisolone Acetate	Prednisolone Acetate	349	11,903	$17,318
Timolol Maleate	Timolol Maleate	68	4,799	$8,132
Ciprofloxacin Hcl	Ciprofloxacin Hcl	326	7,772	$3,339

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
V2203	Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens	N	33	34	$3,112
V2020	Frames, purchases	N	33	33	$1,683
V2103	Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens	N	17	18	$1,275

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$232	Astellas Pharma US Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark A. Gonce, M.D.?

Tedicare shows public-source Medicare data for Mark A. Gonce, M.D. (NPI 1295732840), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark A. Gonce, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark A. Gonce, M.D.?

Mark A. Gonce, M.D. is linked to CHARLOTTESVILLE EYE ASSOCIATES LTD (billing NPI 1548200280) in the available physician profile data.

Does Mark A. Gonce, M.D. have Open Payments data?

Mark A. Gonce, M.D. has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.